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Genetic manipulation of NK cells for 
cancer immunotherapy: techniques 
and clinical implications
Mattias Carlsten* and Richard W. Childs
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Given their rapid and efficient capacity to recognize and kill tumor cells, natural killer (NK) 
cells represent a unique immune cell to genetically reprogram in an effort to improve 
the outcome of cell-based cancer immunotherapy. However, technical and biological 
challenges associated with gene delivery into NK cells have significantly tempered this 
approach. Recent advances in viral transduction and electroporation have now allowed 
detailed characterization of genetically modified NK cells and provided a better under-
standing for how these cells can be utilized in the clinic to optimize their capacity to 
induce tumor regression in vivo. Improving NK cell persistence in vivo via autocrine IL-2 
and IL-15 stimulation, enhancing tumor targeting by silencing inhibitory NK cell receptors 
such as NKG2A, and redirecting tumor killing via chimeric antigen receptors, all represent 
approaches that hold promise in preclinical studies. This review focuses on available meth-
ods for genetic reprograming of NK cells and the advantages and challenges associated 
with each method. It also gives an overview of strategies for genetic reprograming of NK 
cells that have been evaluated to date and an outlook on how these strategies may be 
best utilized in clinical protocols. With the recent advances in our understanding of the 
complex biological networks that regulate the ability of NK cells to target and kill tumors 
in vivo, we foresee genetic engineering as an obligatory pathway required to exploit the 
full potential of NK-cell based immunotherapy in the clinic.
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introduction
Natural killer (NK) cells are immune cells primarily found in the blood, liver, spleen, bone marrow, 
and to a lesser extent, in lymph nodes (1). They were initially identified based on their ability to lyse 
tumor cells without a need for priming (2–5). NK cells are now known to play an important role in 
host immunity against both cancers and certain viral infections (6–8).
NK cells can mediate cytotoxicity via multiple distinct mechanisms. Degranulation is the most 
studied cytotoxicity pathway, where NK cells release cytotoxic granules upon contact with the 
target. Cytotoxicity via this pathway is dictated by a balance of signals from an array of germline 
encoded activation and inhibitory cell surface receptors. Most activation receptors need simultane-
ous co-stimulation by other activation receptors to trigger NK cell cytotoxicity (9). One exception 
from this rule is the Fc receptor CD16, which alone can trigger NK cell degranulation against 
antibody-coated target cells via antibody-dependent cellular cytotoxicity (ADCC) (9). Other 
routes by which NK cells can kill targets are the death receptor pathways TRAIL/TRAIL-R and 
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Fas/FasL. Instead of triggering release of cytotoxic granules, 
death receptor pathways prompt apoptosis via caspase activation 
in target cells.
More than a decade has passed since initial reports established 
the anti-tumor potential of NK cells in patients with cancer. These 
studies showed that haplo-identical donor NK cells could prevent 
relapse in acute myeloid leukemia (AML) following hematopoietic 
stem cell transplantation (HSCT) and that adoptively infused 
mature donor NK cells could induce remission in AML patients 
(6, 10). Despite this revelation, doubts remain about the true 
therapeutic potential of NK cells in cancer immunotherapy. In 
contrast to therapy utilizing T cells, enthusiasm for NK cell-based 
immunotherapy has been tempered by uncertainties about their 
in vivo persistence, and doubts regarding their ability to migrate to 
tumor tissues following adoptive infusions. Although recent data 
have shown CMV reactivation reduces the risk for AML relapse 
following HSCT (11) potentially caused by CMV-induced NK cells 
cross-reacting with AML cells, NK cells, unlike T-cells, lack antigen 
specificity, further tempering enthusiasm for their use as immune 
effectors in cellular therapy.
Genetic manipulation of NK cells to improve their persistence, 
cytotoxicity, tumor targeting capacity, and ability to home to 
disease sites in  vivo holds potential to advance the efficacy of 
NK cell-based cancer immunotherapy. However, until relatively 
recently, the genetic manipulation of NK cells has proven to be 
challenging. Viral transduction, successfully used for T cells, 
has been associated with low levels of transgene expression and 
unfavorable effects on cell viability when used with NK cells. 
Recent optimization of viral transduction and the establishment 
of electroporation technologies for efficient gene transfection have 
revived the enthusiasm for studies evaluating genetic modification 
of NK cells. Investigators around the world are now exploring 
the potential of multiple different NK cell modalities to geneti-
cally reprogram with the overall aim of further improving upon 
their capacity to kill tumors in cancer patients. One example of 
how this technique can be utilized is to introduce genes into NK 
cells coding for gamma-cytokines (IL-2 and IL-15) to induce 
independence from the obligate need of exogenous cytokines 
for proper in  vivo persistence and expansion post infusion. 
This and similar strategies may further improve the efficacy of 
NK cell-based immunotherapy, as tumor regression following 
adoptive NK cell infusions in AML patients has been reported to 
be dependent on their ability to expand in vivo (6), while being 
limited by regulatory T cells also mobilized following exogenous 
cytokine administration (12, 13). The introduction of chimeric 
antigen receptors (CARs) and the down-regulation of inhibitory 
NK cell receptors such as NKG2A are additional examples of 
specific genetic manipulations that can be utilized to improve 
the outcome of adoptive NK cell immunotherapy.
Given their rapid and efficient method of recognizing tumor 
cells, NK cells represent a unique immune cell to genetically 
reprogram in an effort to improve the outcome of cell-based cancer 
immunotherapy. This review focuses on methods for introducing 
transgenes into NK cells and the advantages and limitations of 
such strategies. It also gives an overview of strategies for genetic 
reprograming of NK cells that have been evaluated to date and 
an outlook on how these specific strategies may be best utilized 
in clinic to maximize the anti-tumor potential of NK-cell based 
immunotherapy.
Methods and Challenges with Genetic 
Manipulation of NK Cells: viral 
Transduction versus Transfection
Genetic manipulation of T cells has successfully been used in both 
preclinical and clinical research (14). In contrast, studies on geneti-
cally engineered NK cells have historically been limited by poor 
efficacy of transgene delivery and substantial procedure-associated 
NK cell apoptosis. In this section, we discuss available approaches 
for gene delivery into NK cells, characterizing how each approach 
developed over time while highlighting the positive and negative 
aspects of each method (Box 1).
viral Transduction
The reduced efficacy of viral transduction of NK cells compared 
to T cells may in part be related to the innate properties that 
characterize NK cells. Innate immune receptors, such as pattern 
recognition receptors that recognize foreign genomic material, are 
likely involved in triggering apoptosis of NK cells following viral 
transduction (15). Best results from studies of viral transduction of 
NK cells have been achieved using either NK cell lines or primary 
NK cells that have undergone expansion ex vivo (Table 1). In con-
trast, viral transduction of primary resting human NK cells typically 
Box 1 | Pros and Cons for Methods of Genetic Modification of NK Cells.
Method Pros Cons vector/apparatus used
V
ira
l 
tr
an
sd
uc
tio
n
Stable transgene expression
Well characterized when used with other immune cells (e.g., T cells)
Can be used with gene editing technologies, such as CRISPR
Risk for sustained and uncontrollable adverse events 
due to stable transgene expression
Risk for insertional mutagenesis and immunogenicity
Cellular enrichment may be needed and viability may 
be compromised
Retroviral vectors
Lentiviral vectors
Adenoviral vectors
Vaccinia virus vectors
Tr
an
sf
ec
tio
n High transduction efficiency without compromising viability Transient transgene expression may not be sufficient 
to induce long-term clinical responses
Amaxa
Viral vector independent; less regulatory issues; no need for high-
level biosafety laboratory
BioRad
BTX
Can be used with gene editing technologies, such as CRISPR MaxCyte
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results in substantially lower transduction efficiencies. Most studies 
on viral transduction of NK cells have utilized retro- and lentiviral 
vectors. Although adenoviral- and vaccinia virus vectors have been 
utilized for transduction of NK cells, their use has been limited and 
they will not be discussed further in this review.
Retroviral vectors were the first viral vectors used to genetically 
modify NK cells. The first report on retroviral transduction of 
NK cells was published in the late 1990s and focused on genetic 
manipulation of the NK cell line NK-92 (16). This study reported 
a transduction efficacy of only 2–3%. Optimization of retroviral 
transduction approaches over the past decade has resulted in higher 
transduction efficiencies, especially when used with human NK 
cells that have undergone ex vivo expansion (Table 1). A recent 
report showed that retroviral transduction of ex vivo expanded NK 
cells with genes coding for either IL-15 or membrane bound IL-15 
(mbIL-15) resulted in an average 69 and 71% transduction efficiency, 
respectively (25). Although retroviral transduction of NK cells has 
been reported to not alter the function, phenotype, and proliferative 
capacity of NK cells (20, 23), their viability following retroviral trans-
duction has rarely been reported. A significant deleterious impact on 
the viability of primary NK cells undergoing retroviral transduction 
may preclude utilizing this approach in a clinical setting. Further, 
retroviral transduction also requires active cell division, impeding 
the use of this method with primary non-activated NK cells. This 
limitation is less important when retroviral transduction is utilized 
with NK cell lines such as NK-92 that have continuous and unlimited 
proliferation capacity. However, as discussed later in this review, it 
is important to note that this NK cell line does have phenotypic and 
function differences from primary human NK cells, which may have 
therapeutic implications for clinical therapy.
Lentiviral Vectors
More recently, studies evaluating transduction of NK cells using 
lentiviral vectors have been pursued. In contrast to transduc-
tion with retro- and adenoviral vectors, lentiviral vectors can 
incorporate transgenes into the genome of non-dividing cells. 
Further, lentiviral vectors allow for gene modification of NK cells 
without altering their phenotypic and functional properties as 
occurs following stimulation with i.e., cytokines. The first report 
on the successful use of lentiviral vectors for genetic modification 
TaBle 1 | Overview of techniques used to genetically modify NK cells with reported gene delivery efficacies and effect on cell viability.a
Method NK cell source efficacy (%) viability Reference
V
ira
l t
ra
ns
du
ct
io
n Retroviral vector NK cell lines 1–10 n.r. (16–19)
Resting/short-term activated NK cells 6–50 n.r. (18)
Expanded NK cells 6–96 n.r. (20–25)
Lentiviral vector NK cell lines 2–97 n.r. (26–29) 
Resting/short-term activated NK cells 3–73 n.r. (15, 26, 28, 30, 31)
Expanded NK cells 90 95% (26)
Tr
an
sf
ec
tio
n
Nucleofection (RNA and DNA) NK cell lines 17–48 45–97% (32–35)
Resting/short-term activated NK cells 11 n.r. (33)
Expanded NK cells – – –
Electroporation (RNA and DNA) NK cell lines 1–80 90% (36–39)
Resting/short-term activated NK cells 40–90 86–90% (40, 41)
Expanded NK cells 61–81 89–90% (40, 41)
aOnly those studies that have reported transgene expression following genetic manipulation of NK cell are reported in this table. 
n.r., not reported.
of NK cells was performed in primary murine NK cells (42), with 
subsequent studies establishing that lentiviral transduction of 
human NK cells could also be achieved (Table 1). Although most 
studies have reported lentiviral transduction of NK cell lines with 
efficiencies of 15–40% (27, 28), the efficiency highly varies from 
only a few percent to nearly 100%, and in some cases, multiple 
rounds of transduction are required (26, 29). Recent data indicate 
that transduction efficiencies of primary human NK cells can 
be increased by drug-induced inhibition of intracellular innate 
immune receptors in NK cells (15). Unfortunately, and similar to 
studies utilizing retroviral transduction, the viability of NK cells 
after lentiviral transduction has rarely been reported. Using an 
optimized protocol, our lab has achieved a maximum transgene 
expression in up to 60% of ex vivo expanded NK cells 3 days after 
lentiviral transduction with GFP without incurring any deleteri-
ous effects on NK cell viability, phenotype, or function (Personal 
communication, R. Childs).
In summary, viral transduction of NK cells results in vari-
able transduction efficacies and may require multiple rounds of 
transduction and/or post transduction cell enrichment to achieve 
acceptable transgene expression. Further, viral associated cell death 
and the need for post-transduction enrichment may compromise 
the clinical utility of this approach. Finally, although the risk may 
be low, the possibility of viral-induced insertional mutagenesis 
and immunogenicity (43, 44) occurring post transduction must 
be considered when utilizing this methodology in the clinic. 
Nevertheless, viral transduction of NK cells does achieve stable 
transgene expression which, depending on how the NK cell is being 
genetically modified, might be required to induce a durable and 
long-term clinical response.
Transfection
Compared to viral transduction, transfection of NK cells appears to 
be associated with lower degrees of apoptosis, less inter-individual 
and inter-experimental variability, with transgene delivery efficiency 
being completely independent of cellular division. In most cases, 
this approach results in a more rapid albeit transient expression of 
the transgene as compared to viral transduction where genes must 
first be incorporated into the cellular genome before expression can 
occur. Gene transfer using transfection can be achieved by either 
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electroporation (including nucleofection) or lipofection. Since the 
latter has been used only in a few studies (45), this review will focus 
on strategies utilizing the electroporation approach.
Electroporation is a method where genetic material is delivered 
into cells following a short electric pulse that temporarily induces 
small pores in the cell membrane, allowing charged molecules 
such as DNA and RNA to move into the cell. This technology 
was first used with NK cell lines in the late 1990s (32, 36–38, 46, 
47) and more recently has been used to genetically manipulate 
primary NK cells to express CARs (35, 39, 48) or cytokines for 
autocrine growth stimulation (49). With technological advances 
and the use of mRNA instead of cDNA, transfection efficiencies 
have increased dramatically, reaching up to 90% or more while 
having only a minimal deleterious effect on cell viability (Table 1). 
Remarkably, using mRNA electroporation, transfection efficiencies 
of 80–90% can be achieved in not only ex vivo expanded cells but 
also in primary resting (non-cytokine activated) human NK cells 
(40). Despite this remarkable advance, a detailed characterization 
on the effects of electroporation on the phenotype, function, and 
proliferative capacity of NK cells following electroporation has yet 
to be published.
As electroporation does not involve viral vectors, its use in the 
preclinical and clinical setting is associated with less regulatory 
issues. Also, as indicated above, electroporation most often leads to 
transient transgene expression, which may be viewed favorably from 
a safety perspective when new transgenes with unknown potential 
toxicities are being explored in early clinical trials. Regimens that 
use DNA electroporation technology have been employed to 
generate stable transgene expressing cells. Although the efficacy 
of this approach is typically lower than that achieved with viral 
transduction, it may be improved if combined with targeted 
integration techniques that avoid random integration in inactive 
heterochromatin regions. Such strategies also reduce the risk for 
off-target effects, including gene silencing due to random integra-
tion in active genes and integration in hot-spots that may trigger 
malignant transformation. With advantages in design of guiding 
RNAs and by having better on-target specificity compared to other 
gene editing technologies such as  Zink-Finger nuclease (ZFN) 
and the transcription activator-like effector nucleases (TALEN) 
technologies, the recently developed clustered regularly interspaced 
short palindromic repeats (CRISPR) technique has rapidly become 
a popular tool for targeted gene integration (50). The CRISPR/
Cas9 system induces permanent modifications at specific sites of 
the genome via double-strand breaks (DSBs), and can be used to 
integrate new genes at specific sites via homology-directed recombi-
nation (50). Although only moderate degrees of genome integration 
are currently being achieved with this technique today, the CRISPR/
Cas9 system could be used to produce stably transduced NK cells 
by gene editing of primary NK cells prior to their ex vivo expansion.
Gene Modification Strategies aimed at 
improving the efficacy of NK Cell-Based 
Cancer immunotherapy
With new advances in the field, genetic manipulation of NK cells has 
opened up possibilities to study many different pathways involved in 
NK cell tumor targeting and the ability to genetically modify NK cells 
to improve their tumor cytotoxicity. Here, we will discuss reported 
gene modification strategies that can improve in vivo persistence and 
expansion, tumor tissue migration, and the tumor targeting capacity 
of adoptively infused NK cells (Figure 1, Table 2 and Box 2).
Strategies to improve Persistence and 
expansion of infused NK Cells
In vivo persistence and expansion of infused NK cells have been 
shown critical for inducing tumor regression following adoptive 
NK cell infusion (6). Using retroviral transduction of the IL-2 
gene into NK-92 cells, Nagashima et al. were able to propagate 
this NK cell line for up to 5 months in vitro without the addition 
of exogenous cytokines (16). Further, IL-2-expressing NK-92 cells 
where shown to also have enhanced tumor cytotoxicity compared 
to non-transduced parental NK-92 cells that were stimulated with 
exogenous IL-2. In line with these in vitro findings, these genetically 
modified cells showed improved in vivo persistence and anti-tumor 
responses when infused into tumor-bearing mice. Similar data 
with IL-2 gene delivery in expanded NK cells were reported by 
Konstantinidis et al. (51). As observed with IL-2 transduced NK-92 
cells, retroviral transduction of ex vivo expanded NK cells with the 
mbIL15 gene also dramatically increased their survival in vitro; 
median cell recovery was 85% for mbIL-15 NK cells after 7 days 
in culture without IL-2, whereas mock-transduced NK cells were 
NK
NK
NK
P
er
si
st
en
ce
M
ig
ra
tio
n
C
yt
ot
ox
ic
ity
Autocrine cytokine stimulation
Introduction of
chemokine receptors
and
adhesion molecules
Blood vessel
NK cells
Introduction of
CARs or aNKRs
Silencing of
iNKRs
Autocrine
cytokine
stimulation
Protection from
suppressor
cytokines Tumor cells
Tumor Tumor Tumor Tumor
FiGuRe 1 | Schematic overview of how genetic manipulation can be 
can be used to improve the efficacy of NK cell-based cancer 
immunotherapy in the clinic. Genetic engineering of NK cells to promote 
persistence and expansion by autocrine cytokine stimulation, migration to the 
tumor tissue via introduction of receptors involved in cellular homing (i.e., 
chemokine receptors and adhesion molecules), as well as bolstering their 
anti-tumor cytotoxicity via introduction of CARs or activating NK cell 
receptors (aNKRs) or via silencing of inhibitory NK cell receptors (iNKRs), 
protection from suppressive cytokines in the tumor environment, and 
boosted function via autocrine cytokine stimulation.
TaBle 2 | Overview of strategies evaluated for improving the anti-tumor 
efficacy of primary human NK cells and NK cell lines in vitro and in 
preclinical animal models.
Modality Strategy Molecule Method Reference
Persistence/
expansion
Cytokine 
stimulation
IL-2 RV (16, 51)
IL-15/mbIL-15 RV, EP, LV (25, 29, 49, 52)
Migration – – – –
Cytotoxicity Redirected 
targeting
αCD19 CAR RV, LV, EP (28, 39–41, 53)
αCD20 CAR RV, LV, EP (28, 53, 54)
αCD33 CAR EP (38)
αCD138 CAR LV (24, 48)
αCS1 CAR LV (55)
αGD2 CAR RV (23, 56)
αHER2 CAR RV, EP (22, 57)
αerbB2 CAR EP (35)
αCEA CAR EP (36)
αEpCAM CAR LV (29)
αNKG2D-L CAR RV (58)
αTRAIL-R1 CAR RV (58)
αGPA7 RV (19, 59)
ADCC HA-CD16 RV (19)
Cytokine 
stimulation
IL-2 RV (16)
IL-15/mbIL-15 RV, LV, EP (25, 29, 49, 52)
Protection from 
suppressive 
cytokines
DNTβRII EP (34)
Receptor 
silencing
NKG2A (shRNA) LV (31)
RV, retroviral transduction; LV, lentiviral transduction; EP, electroporation; ADCC, 
antibody-dependent cellular cytotoxicity; HA-CD16, high-affinity CD16; DNTβRII, 
double negative TGF-β RII.
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essentially undetectable (25). Hence, the strategy of introducing 
genes coding for gamma-cytokines to improve in  vivo NK cell 
persistence and expansion following infusion independent of 
exogenous cytokine administration appears promising.
Strategies to enhance Migration of infused  
NK Cells
Proper tumor tissue homing of infused NK cells is a prerequisite 
for their ability to induce tumor regression. However, studies char-
acterizing the in vivo migration capacity of adoptively infused NK 
cells have been largely overlooked (60). Recent evidence suggests 
non-expanded and expanded NK cells have different migration 
patterns when infused into animal models (61). Moreover, using 
trogocytosis to transfer premade cell surface molecules from 
a feeder cell line to NK cells, Somanshi et  al. have shown that 
migration of infused NK cells can be redirected by equipping them 
with the lymph node homing receptor CCR7 (62). Despite these 
data, no study has so far used gene modification techniques to 
actively direct infused NK cells to selected organs. Based on data 
from Somanshi et al., we have been able to use mRNA transfec-
tion to genetically engineer NK cells with the CCR7 receptor to 
improve their migration toward one of its ligands CCL19 (Carlsten 
M., Manuscript in preparation, April 2015). Other strategies may 
involve utilizing chemokine receptors, such as CXCR3 to improve 
NK cell migration to inflamed tissues, such as those infiltrated with 
metastatic tumors (63).
Strategies to increase Tumor Cytotoxicity by 
infused NK Cells
The majority of reports on expression of transgenes in NK cells 
have characterized the effects of CARs in NK cell lines, expanded 
NK cells, and primary non-expanded NK cells (Table 2). CARs 
are engineered receptors that have the extracellular specificity of 
an antibody combined with potent intracellular signaling adaptors 
such as CD3ζ, CD28 and/or 4-1BB. Importantly, these receptors 
do not require stimulation through co-receptors to trigger robust 
anti-tumor cytotoxicity. The recent breakthrough success of anti-
CD19 CAR T cell therapy in patients with B cell malignancies has 
stimulated the research community to develop and investigate a 
wide array of CARs against multiple different epitopes expressed 
on numerous tumor types (64). Several of these CARs have been 
explored in NK cells (Table 2). CD19 and CD20 specific CARs 
against B cell malignancies (39–41, 53, 54), and CARs targeting 
CD33 on leukemia cells (38), CS1 and CD138 on myeloma cells 
(24, 48, 55), GD2 on neuroblastoma cells (23, 56), Her2/Neu and 
erbB2 on breast cancer cells (22, 35), carcinoembryonic antigen 
(CEA) on colon cancers (36), EpCAM on epithelial tumors (29), 
GPA7 on melanoma (59), NKG2D ligand on leukemia and solid 
tumors, and TRAIL-R1 on various tumor targets (58) have all been 
shown to have the capacity to redirect NK cell cytotoxicity against 
their target antigens. The majority of these studies have used viral 
vectors to transduce CARs into the NK cell, albeit electroporation 
has also been used in a few studies (Table 2).
Based on clinical data showing superior response rates in 
rituximab-treated lymphoma patients homozygous for the high-
affinity CD16-158V polymorphism (HA-CD16) compared to those 
who carry the low-affinity CD16-158F (LA-CD16) polymorphism 
(65, 66), several groups have recently addressed whether introduc-
tion of the HA-CD16 gene into NK cells lacking this polymorphism 
can be used as a strategy to augment ADCC against tumors. This 
approach has appeal as only a minority of patients is homozygous 
for HA-CD16 (67). Moreover, in contrast to CAR NK cells, infusions 
of NK cells genetically modified to express HA-CD16 may be used 
to improve the outcome of virtually any malignancy for which there 
is an FDA approved IgG1 antibody, without the expectation for 
any severe off target side-effects. In vitro experiments conducted by 
Binyamin and colleagues showed significantly improved cytotoxicity 
against a rituximab-coated B lymphoma cell line following stable 
transduction of the CD16 negative NK-92 cell line with HA-CD16 
compared to NK-92 cells were equipped with LA-CD16 (19). 
Recently, our group explored a similar approach, where ex vivo 
expanded NK cells from CD16-158F/F (LA-CD16) donors were 
Box 2 | examples of NK Cell Modalities to Gene Manipulate for 
improved Clinical efficacy.
Persistence/
expansion
Autocrine cytokine production (IL-2, IL-15, and mbIL-15)
Migration CCR7 and CXCR3
Cytotoxicity CARs, CD16, autocrine cytokine production (IL-2 and IL-15), 
and overexpression of double negative TGF-β II receptor to 
avoid suppressive effects of TGF-β. Silencing of inhibitory NK 
cell receptors, such as NKG2A
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found to have substantially augmented ADCC following electropo-
ration with mRNA coding for the HA-CD16 (68). These data suggest 
the addition of the HA-CD16 gene to patient NK cells that already 
express endogenous CD16 can be used to augment their ability to 
induce ADCC, and that this approach could be used as a strategy to 
improve the efficacy of antibody-based therapies for cancer patients.
Introduction of genes that render NK cells insensitive to 
suppressive cytokines such as TGF-β, thereby preserving their 
cytotoxicity, has also been studied. Yang et al. generated an NK-92 
cell line resistant to the suppressive effects of TGF-β by geneti-
cally modifying them to express the dominant negative mutant 
form of TGF-β type II receptor (DNTβRII) on their surface (34). 
Adoptive transfer of these TGF-β insensitive NK-92 cells in lung 
cancer-bearing mice was associated with increased levels of IFN-γ 
released from the infused cells and resulted in increased survival 
rates compared to mice treated with wild-type NK-92.
Genetic reprograming of NK cells may also be directed to 
achieve specific protein silencing with the aim of improving tumor 
targeting by circumventing NK cell inhibitory signals induced upon 
interaction with tumor cells. Initial studies have focused on the use 
of shRNA technology for this purpose. In this context, shRNAs 
expressed inside cells are processed by the Dicer endonuclease 
complex to generate double-stranded small interfering RNAs that 
prevent translation of their target mRNAs (69), shRNAs have been 
used successfully to knock-down expression of the HLA-E-binding 
inhibitory NK cell receptor NKG2A (31). Using an inducible vec-
tor in IL-2 activated NK cells, Figueiredo et al. observed a 40% 
increased killing capacity against the HLA-E expressing cell line 
K562 HLA-E. Using a similar approach with the NK cell line NKL, 
our group observed increased killing capacity of HLA-E expressing 
721.221 cells in vitro and in a preclinical mouse model (70). Further 
details on protocols for shRNA-mediated protein silencing in NK 
cells can be found in Purdy et al. (71). To date, studies utilizing 
CRISPR, ZFN, or TALEN to genetically modify NK cells to silence 
their inhibitory receptors for the same purpose of enhancing the 
anti-tumor capacity of NK cells have not yet been reported.
In conclusion, an array of gene modification strategies for NK 
cells has now been reported. Several of them hold promise for 
improving clinical responses of NK cell-based cancer immuno-
therapy. However, to date, few have been translated into clinical 
studies. The following section will discuss how these strategies 
can be incorporated in clinical NK cell cancer immunotherapy.
Considerations for the Development of 
Clinical Protocols using Genetically 
engineered NK Cells
Challenges associated with genetic manipulation of NK cells 
have significantly delayed the debut of this strategy in clinical 
cancer therapy. While recently initiated trials (NCT00995137 
and NCT01974479) exploiting the role for CAR19-expressing ex 
vivo expanded NK cells in patients with B cell malignancies will 
give us a first insight into the potential of this approach; further 
optimization of clinical compliant methods for genetic modifica-
tions of NK cells is needed to exploit the full clinical potential 
of this approach. Moreover, additional research on the multiple 
aspects of NK cell tumor targeting that could be modified with this 
technique is needed. Although clinical responses following infu-
sion of NK cells may be further improved by simply augmenting 
their tumor targeting capacity, studies evaluating the potential of 
this technology to improve the persistence of infused cells as well 
as avenues to promote proper NK cell migration and homing to 
the tumor tissue are also warranted (Figure 1).
Genetic engineering of NK cells to make them cytokine independ-
ent and thereby improve persistence, while boosting their cytotoxic 
capacity, may be one avenue to further explore. The advantage with this 
approach would be that exogenous cytokines would be unnecessary 
following NK cell infusion, which may reduce the risk of mobilizing 
regulatory T cells that directly suppress NK cell cytotoxicity (13). 
Challenges with taking this approach to a clinical context include 
the risk of inducing a cytokine release syndrome due to massive and 
unregulated NK cell proliferation. This approach also comes with 
the potential risk of inducing malignant transformation of the NK 
cells due to permanent autocrine growth stimulation, as have been 
observed for IL-2 engineered T cells (72). However, such scenarios 
may be avoided if genes coding for IL-2 or IL-15 are only temporar-
ily introduced via mRNA electroporation of NK cells. Should stable 
transgene expression be required to induce proper tumor regression, 
an alternative strategy to prevent runaway NK cell proliferation would 
be to introduce an inducible suicide gene in the modified cells (73).
Migration to the tumor tissue is another aspect governing 
proper tumor targeting. This aspect has been largely overlooked 
and could potentially improve clinical outcome if infused NK 
cells are redirected to the tumor site instead of circulating non-
specifically into mostly non-tumor-bearing tissues. No studies 
aimed at improving the in vivo homing of infused gene engineered 
NK cells have yet been published.
As discussed above, numerous strategies for redirecting or boost-
ing NK cell tumor killing in vitro have been explored. Introduction 
of CARs represent the most studied and developed approach that 
has recently reached clinical evaluation (Table 2). Expression of 
the high-affinity CD16 may soon also be tested in a clinical setting 
as this approach can be combined with already clinically available 
monoclonal antibodies that target an array of antigens expressed on 
a variety of different tumor types. Bolstering NK cell cytotoxicity 
via autocrine cytokine stimulation or via silencing of inhibitory NK 
cell receptors will likely require additional evaluation in preclinical 
animal models before they can be incorporated in clinical protocols. 
Once all these strategies are fully characterized pre-clinically, they 
may be combined to further improve the full anti-tumor potential of 
adoptively transferred NK cells. For instance, introduction of a CAR 
while simultaneously silencing the NKG2A inhibitory receptor may 
represent one such future approach. One can also consider adding 
autocrine cytokine stimulation to further improve cytotoxicity 
while simultaneously supporting their in  vivo persistence. As 
NK cell degranulation is regulated by a balance of activating and 
inhibitory signals from well-defined cell surface receptors, it may 
also be possible to add CARs or other activation receptors together 
with selected receptors that mediate inhibition via ligands that are 
expressed on normal tissues (and not tumor cells), thereby giving 
genetically reprogramed NK cells an additional layer of target 
specificity. However, many additional preclinical studies will be 
needed before these approaches can reach clinic.
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The choice of method for genetic reprograming of NK cells is 
another important factor that needs to be considered when tak-
ing genetically engineered NK cells to clinical evaluation. Viral 
transduction has the advantage of stable expression; however, 
as mentioned above, viral transduction of NK cells, especially 
primary cells, does not always lead to a satisfactory level of 
transgene expression and may require multiple rounds of transduc-
tion followed by selection of transgene positive cells. Moreover, 
proper expression of transgenes induced by viral transduction 
can take days, which may be of disadvantage since the lifespan 
of an NK cell may be relatively short following adoptive transfer 
(i.e., weeks). Future studies are warranted to better understand 
if multiple infusions of transfected NK cells can compensate 
transient transgene expression or if stable transgene expression is 
a prerequisite for inducing clinical responses following adoptive 
transfer of genetically engineered NK cells. Studies are also needed 
to fully understand the lifespan of NK cells, particularly those that 
have undergone ex vivo manipulation.
The optimal method for genetic manipulation of NK cells 
to be used in a clinical trial may also depend on what NK 
cell preparation is used (Box 3). The advantage with NK cell 
lines is that they can be utilized as an off-the-shelf product 
stably transduced to express the gene or genes of interest. They 
may also be long-lived if given the proper cytokine support. 
However, the downside with using NK cell lines, like NK-92, 
is the requirement for irradiation (10 Gy) prior to infusion to 
avoid the risk of engrafting cells that are potentially tumorigenic 
in vivo (74). Moreover, patients treated with infusions of NK cell 
lines would also need moderate to high level of preconditioning 
to suppress host immunity to avoid rejection of these allogeneic 
cells. Moreover, infusion of allogeneic cells can raise humoral 
immunity and lead to adaptive T-cell immune responses specifi-
cally against alloantigens, precluding repeated infusions even 
with the use of preconditioning. Similar allo-reactivity can be 
induced with the use of primary allogeneic NK cell infusions. 
The use of autologous NK cells circumvents these risks and 
precludes the need for preconditioning. The potential draw back 
with using autologous NK cells is that efficient tumor targeting 
can be prevented by inhibitory KIR interactions with self-HLA. 
A potential advantage with using an NK cell line versus primary 
NK cells is that large numbers of NK cells from the NK cell line 
can be infused, whereas the number of primary cells available 
for infusion are typically much more limited. However, this 
limitation has recently been circumvented by a number of highly 
efficient methods to expand primary NK cells ex vivo for clinical 
infusion (60). Ideally, infusion of autologous gene-modified NK 
cells can be used to avoid the rejection risk and the prerequisite 
for preconditioning. One approach to overcome limitations of 
autologous NK cell inactivation via self-HLA is to genetically 
modify these effectors to silence inhibitory self-HLA binding 
receptors, such as NKG2A and KIRs, which alone or in combina-
tion with for instance CARs, can improve the tumor targeting 
capacity of NK cells in the autologous setting.
Concluding Remarks
Anti-tumor antibodies and CAR T cells have established immu-
notherapy as a viable treatment option for patients with cancer. 
Given their rapid and efficient method of recognizing tumor cells, 
NK cells represent a unique immune cell to genetically reprogram 
in an effort to improve the outcome of cell-based cancer immuno-
therapy. However, technical and biological challenges associated 
with gene delivery into NK cells have significantly tempered this 
approach. Viral transduction of NK cells initially resulted in 
low transgene delivery efficiencies that often required multiple 
rounds of transduction and/or cellular enrichment to achieve 
acceptable numbers of transgene expressing cells. Nevertheless, 
recent improvements in retro- and lentiviral transduction of NK 
cells have led to a flurry of preclinical studies on gene engineered 
NK cells. A number of studies have also shown that NK cells 
can be genetically reprogramed using mRNA electroporation. 
In contrast to viral transduction, this approach offers high 
transfection efficiencies without compromising their viability 
and does not require high-level biosafety laboratories. Although 
promising preclinical data on mRNA electroporated NK cells 
have emerged recently, concerns have been raised regarding 
the clinical utility of this approach as it only results in transient 
transgene expression.
Recently initiated clinical trials will soon give insight into 
the potential effectiveness of cell-based cancer immunotherapy 
strategies that utilize genetically modified NK cells. Nevertheless, 
further optimization of both viral transduction and electropo-
ration of NK cells is still needed before this approach can be 
fully exploited in the clinic. With the recent advances in our 
understanding of the complex biological networks that regulate 
the capacity of NK cells to target and kill tumors in vivo, and 
with rapid developments in clinically compliant techniques to 
genetically manipulate NK cells, we foresee genetic engineering 
as an obligatory pathway to exploit the full potential of adoptive 
NK cell immunotherapy in patients with cancer.
Box 3 | NK Cell Source for adoptive NK Cell Cancer immunotherapy.
NK cell source Pros Cons
NK cell lines (NK-92) Readily available Preconditioning needed
Easy to gene manipulate Host immunity against alloantigens limits repeated  
infusions and in vivo persistence?
Primary non-expanded NK cells Autologous cells, no rejection. No need for cell  
expansion ex vivo
Low number
Primary ex vivo expanded NK cells High numbers of highly activated autologous cells  
available for repeated use
GMP laboratory needed for expansion
Costs for reagents
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